Second Alzheimer's drug in pipeline
New research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening. Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large study.